

## **Human Bcl9-2 Antibody**

Antigen Affinity-purified Polyclonal Sheep IgG Catalog Number: AF4967

DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects endogenous human Bcl9-2 in Western blots.		
Source	Polyclonal Sheep IgG		
Purification	Antigen Affinity-purified		
Immunogen	E. coli-derived recombinant human Bcl9-2 Met38-Val206 Accession # Q86UU0		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.		


#### APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	1 μg/mL	See Below

#### DATA

### Western Blot



Detection of Human Bcl9-2 by Western Blot. Western blot shows lysates of A172 human glioblastoma cell line and MCF-7 human breast cancer cell line. PVDF membrane was probed with 1 μg/mL of Human Bcl9-2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4967) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Bcl9-2 at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

# PREPARATION AND STORAGE

Reconstitution Reconstitute at 0.2 mg/mL in sterile PBS

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

\*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

## Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

### BACKGROUND

Bcl9-2 (B-cell lymphoma 9-like protein; also Bcl9L and B9L) is a 200-220 kDa transcriptional regulator that belongs to the Bcl9 family of proteins. It is expressed in multiple tissues, particularly breast, and serves to recruit Pygopus to the Wnt-pathway β-catenin-TCF complex in the nucleus. Bcl9-2 and Bcl9 are considered evolutionary duplicates of Legless that perform the same task with different regulation. Human Bcl9-2 is 1499 amino acids (aa) in length. It contains two Pro-rich regions (aa 280-493 and 891-1378). There are four potential alternate start sites at Met879, Met1000, Met708 and Met472. The last two start sites are accompanied by a deletion of aa 1241-1286, and a 62 aa substitution for the C-terminal 167 aa, respectively. Over aa 38-206, human Bcl9-2 is 94% aa identical to mouse Bcl9-2. Bcl9-2 has been identified as a phosphoprotein in several human cancer cell lines and mouse liver.

Rev. 2/6/2018 Page 1 of 1

